Thermo Fisher Expands its Direct-to-Patient Service Offerings
Shots:
- The company has expanded its Direct-to-Patient service offerings for supporting decentralized clinical trials to lessen clinical trial lengths and costs while increasing patient enrollment and participation rates
- The company’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched in early 2020 to ensure that clinical trial patients have uninterrupted access to life-saving drug shipments without visiting a clinic
- The Direct-to-Patient services include Pharmacy-to-Patient- Depot-to-Patient- and Clinical Site-to-Patient services- enabling clinical trial medication delivered directly to patients' homes. Clinical Site-to-Patient services are available in 47 countries- supporting 1-500+ shipments to patients globally
Ref: PRNewswire | Image: Tele Trader
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com